(Q33411755)

26 July 2017

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts (English)

1 reference

26 July 2017

1 reference

1 reference

21

Hagop M Kantarjian

1 reference

26 July 2017

22

Srdan Verstovsek

1 reference

26 July 2017

5

Josef T Prchal

1 reference

26 July 2017

1

Moshe Talpaz

1 reference

26 July 2017

13

Olatoyosi Odenike

1 reference

26 July 2017

11

Elliott F Winton

1 reference

26 July 2017

Susan Erickson-Viitanen

17

object named as

Susan Erickson-Viitanen

1 reference

26 July 2017

2

Ronald Paquette

1 reference

26 July 2017

Lawrence Afrin

3

1 reference

26 July 2017

Solomon I Hamburg

4

1 reference

26 July 2017

Katarzyna Jamieson

6

1 reference

26 July 2017

Howard R Terebelo

7

1 reference

26 July 2017

Gregory L Ortega

8

1 reference

26 July 2017

Roger M Lyons

9

1 reference

26 July 2017

Ramon V Tiu

10

1 reference

26 July 2017

Kavita Natrajan

12

1 reference

26 July 2017

David Claxton

14

1 reference

26 July 2017

Wei Peng

15

1 reference

26 July 2017

Peter O'Neill

16

1 reference

26 July 2017

Lance Leopold

18

1 reference

26 July 2017

Victor Sandor

19

1 reference

26 July 2017

Richard S Levy

20

1 reference

26 July 2017

language of work or name

1 reference

29 October 2013

1 reference

Journal of Hematology & Oncology

26 July 2017

1 reference

26 July 2017

6

1 reference

26 July 2017

1

1 reference

26 July 2017

81

1 reference

https://scigraph.springernature.com/pub.10.1186/1756-8722-6-81

26 July 2017

0 references

cites work

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

One thousand patients with primary myelofibrosis: the mayo clinic experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

How I treat symptomatic splenomegaly in patients with myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

The Jak-Stat pathway in normal and perturbed hematopoiesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Guideline for the diagnosis and management of myelofibrosis.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-8722-6-81

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176265

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

31 October 2018

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

Myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-8722-6-81

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference